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Background: There is currently no consensus on the correlations between androgen concentrations in prostate tissue
and blood and stage and pathological grade of prostate cancer. In this study, we used a newly-developed ultra-sensitive
liquid-chromatography tandem mass spectrometry method to measure testosterone (T) and dihydrotestosterone (DHT)
concentrations in blood and needle biopsy prostate specimens from patients with prostate cancer.
Methods: We analyzed androgen levels in 196 men diagnosed with prostate cancer. All patients had undergone
systematic needle biopsy, and an additional needle biopsy from the peripheral zone was conducted for the simultaneous
determination of T and DHT. We analyzed the relationships between T and DHT levels in tissue and blood and Gleason
score, clinical stage, and percentage of positive biopsy cores, using multivariate analysis.
Results: The median T and DHT levels in blood were 3551.0 pg/mL and 330.5 pg/mL, respectively. There was a strong
correlation between serum T and DHT. The median T and DHT levels in prostate tissue were 0.5667 pg/mg and
7.0625 pg/mg, respectively. In multivariate analysis, serum prostate-specific antigen and tissue T levels were significantly
associated with poor prognosis; high T levels in prostate tissue were significantly related to high Gleason score (p = 0.041),
advanced clinical stage (p = 0.002), and a high percentage of positive biopsy cores (p = 0.001).
Conclusions: The results of this study indicate that high T levels in prostate tissue are related to high Gleason score,
advanced clinical stage, and a high percentage of positive biopsy cores in patients with prostate cancer. T level in needle
biopsy specimens may therefore be a useful prognostic factor in prostate cancer patients.
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Prostate cancer is the most common internal cancer and
the second most frequent cause of cancer-related deaths
among men in the United States. Although the incidence
of prostate cancer in Japan is lower than in the United
States, it has been gradually increasing in recent years.
The etiology of prostate cancer is unclear, but it is
thought to be multifactorial, with genetic, dietary, and
environmental causes. Although prostate cancer initially
responds to androgen ablation therapy, most patients* Correspondence: miyoyasu@med.yokohama-cu.ac.jp
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ment failure.
The ability to predict prostate tumor behavior is im-
portant, because more intensive treatment is necessary to
prevent the development of castration-resistant prostate
cancer (CRPC). Pathological grade and clinical stage can
strongly predict tumor aggressiveness, but no useful
molecular markers have yet been identified. Several
previous studies have reported blood and prostate
tissue levels of testosterone (T) and dihydrotestosterone
(DHT) in patients with prostate cancer, but these studies
have involved small sample sizes, and several have
measured the levels using radioimmunoassays (RIAs),
which require a large amount of tissue (≥20 mg) forl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics
No. patients 196
Age, years (mean, SD) 70.6 (7.334)
PSA, ng/mL (median, 95% CI) 11.5 (32.43–82.73)
Prostate volume, cm3 (median, 95% CI) 27.7 (29.83–34.91)
Gleason score ≤7, ≥8 (%) 130 (67.4), 63 (32.6)
Clinical stage≤ III, ≥IV (%) 166 (86.0), 27 (14.0)
% Positive core <30%, ≥30% (%) 143 (74.1), 50 (25.9)
SD: Standard deviation; PSA: Prostate-specific antigen; CI: Confidence interval.
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http://www.biomedcentral.com/1471-2407/14/717androgen measurement [1,2]. There have been few reports
regarding the correlation between prostate cancer ag-
gressiveness and androgen concentrations measured in
smaller prostate tissue samples, such as those obtained
by needle biopsy.
Advancements in liquid-chromatography tandem mass
spectrometry (LC-MS/MS) methods mean that T and
DHT levels can be measured in small tissue samples
with high sensitivity and reliability [3-6]. LC-MS/MS can
be used to measure androgen concentrations in tissue
samples as small as those obtained by a single needle biopsy
(approximately 3 mg), and the latest LC-MS/MS technique
is more than 10 times as sensitive as the RIAs used in the
past, especially in the lower concentration range [7].
Previous reports revealed that T levels were higher and
DHT levels lower in prostate cancer tissues compared
with tissues from patients with benign prostatic hyperpla-
sia, although there is currently no consensus on androgen
concentrations in prostate cancer tissues from men with
different stages and with different pathological grades of
disease [6,8-10]. Moreover, the relationship between tissue
androgen concentrations and tumor behavior in prostate
cancer is not clear. In the present study, we measured
androgen (T and DHT) levels in blood and prostate
tissues using LC-MS/MS and analyzed the correlations




A total of 359 patients with suspected prostate cancer
underwent prostate needle biopsy for primary pathological
diagnosis at major cancer treatment facilities in Japan
between April 2000 and July 2003. Blood samples were
also collected. All blood samples were taken between
09.00 h and 15.00 h to minimize the effect of daily T
variations. Patients underwent a systematic needle biopsy.
An additional needle biopsy sample was taken from the
peripheral zone of the prostate as a chemical biopsy,
for the simultaneous determination of T and DHT. The
tissues were immediately frozen at −70°C. Of the 359
patients, 163 were shown not to have cancer and data for
the remaining 196 men diagnosed with prostate cancer
were analyzed. The patient characteristics are shown in
Table 1.
T and DHT concentrations in prostate tissues and
blood were determined by LC-MS/MS. The method was
validated to ensure that the result was within the 20%
range for accuracy and precision [7]. The determination
limit of the method was 0.5 pg/shot for T and 1 pg/shot
for DHT. The concentrations of T and DHT were sub-
sequently expressed in pg/mg.
We analyzed the relationships between T and DHT
levels in prostate tissue and blood and prognostic factorsincluding Gleason score, clinical stage, and percentage of
positive biopsy cores (% positive cores) using multivariate
analysis. All prostate biopsy samples were reviewed by a
central pathologist. Informed consent was obtained from
all patients and the experimental procedures were con-
ducted in accord with the ethical standards of the Helsinki
Declaration. This study was approved by each of the par-
ticipating institution’s review boards (Additional file 1).
Biological samples
Each needle chemical biopsy prostate sample (2–8 mg)
from patients with prostate cancer was placed in a
microtube and frozen immediately in liquid nitrogen or
in a dry-ice box, and then stored at −70°C until hormone
analysis. Serum samples were separated from blood and
stored at −70°C until analysis.
Chemicals and materials
T, DHT, [16,16,17α-2H3]-T (T-d3), and [16,16,17α-
2H3]-
DHT (DHT-d3) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). The Bond Elut C18 cartridge was
purchased from Varian (Palo Alto, CA, USA), and 4-
dimethylaminopyridine (DAP), 2-methyl-6-nitrobenzoic
anhydride (MNBAn), and picolinic acid (PA) were
purchased from Tokyo Kasei Industry (Tokyo, Japan).
Triethylamine (TEA) was purchased from Wako Pure
Chemical Industries (Osaka, Japan). The Cadenza CD
C-18 columns and Capcell Pak SCX UG80 pre-columns
were purchased from Intact (Kyoto, Japan) and Shiseido
(Tokyo, Japan), respectively.
The derivatization reagent was prepared as follows:
10 mg DAP, 20 mg MNBAn, and 25 mg of PA were
dissolved in 1 mL of tetrahydrofuran and the mixture
was agitated until it became cloudy or crystals appeared.
The reagent solution was used after 3–5 min [5]. Serum
prostate-specific antigen (PSA) levels were measured
using a DPC Imrise third generation PSA assay kit.
LC-MS/MS
Serum hormone levels were determined by LC-MS/MS,
as described by Yamashita et al. [5]. T and DHT levels in
prostate tissue samples were measured using an API-
5000 triple-stage quadrupole mass spectrometer (Applied
Miyoshi et al. BMC Cancer 2014, 14:717 Page 3 of 7
http://www.biomedcentral.com/1471-2407/14/717Biosystems, Foster City, CA, USA) connected to a Shimadzu
LC-20 AD pump and Shimadzu SIL HTC autosampler
(Shimadzu, Kyoto, Japan) and an electrospray ionization
(ESI) ion-source device. The columns used were a Capcell
Pak SCX UG80 pre-column (35 mm× 2 mm internal
diameter, particle size 5 μm) and a Cadenza CD-C18 ana-
lytical column (150 mm× 3 mm internal diameter, particle
size 3 μm), which had been maintained at 40°C.
The mobile phase consisted of CH3CN-MeOH (50:50,
v/v) (solvent A) and 0.1% formic acid (solvent B). For
gradient elution, A/B was used at a ratio of 60/40–90/10
between 0 and 5.0 min, and 90/10–100/0 between 5.0
and 7.0 min. Solvent A alone was used between 7.0 and
9.0 min. A/B was used at 100/0–60/40 between 9.0 and
11 min. The flow rate was 0.4 mL/min. The following ESI
conditions were used: spray voltage, 3,300 V; collision
gas, nitrogen, 45 psi; curtain gas, 11 psi; ion source
temperature, 600°C; and ion polarity, positive.
Tissue hormone analysis
Each frozen prostate tissue sample (1–3 mg, 5–13 mm)
was weighed and then a piece of the sample was cut off
with scissors. Purified water (0.5 mL) was added to the
cut sample, which was then homogenized for 20 s using
an Ultra-Turrax homogenizer with an ice-cooling bath,
and then washed with 0.5 mL water. Ethanol (3 mL)
and 100 pg of T-d3 and DHT-d3 were added to the
homogenate and the mixture was shaken at 50°C for
2 h. The solution was allowed to stand at 4°C overnight
to allow complete precipitation of the protein. After
centrifugation (4°C, 3,000 rpm, 10 min), the supernatant
was isolated and the solvent was evaporated using a
centrifugation evaporator. The residue was dissolved in
methanol (0.25 mL), diluted with purified water (1 mL),
and loaded onto a Bond Elut C18 cartridge pre-conditioned
with methanol (6 mL) and purified water (6 mL). The
cartridge was washed with purified water (1 mL) followed
by 30% acetonitrile solution (v/v, 3 mL). T and DHT were
subsequently eluted with 70% acetonitrile solution (v/v,
3 mL) and the solvent was removed using a centrifugation
evaporator.
The residue was dissolved in 100 μL reagent mixture,
prepared as described above. TEA (20 μL) was added
and the resulting mixture was allowed to stand at room
temperature for 30 min. After dilution of the reaction
mixture with 1% acetic acid solution (v/v, 1 mL) to stop
the reaction, the resulting derivative was loaded onto a
Bond Elut C18 cartridge pre-conditioned with methanol
and purified water. The cartridge was washed with puri-
fied water (1 mL) followed by 40% acetonitrile solution
(v/v, 3 mL). The derivatives were then eluted with 80%
acetonitrile solution (v/v, 3 mL). The solvent was evap-
orated to dryness using a centrifugation evaporator at
53–55°C, the residue was dissolved in 40% acetonitrilesolution (v/v, 100 μL), and a 40-μL aliquot of the solution
was subjected to LC-ESI-MS/MS.
Validation of analytical methods
The inter- and intra-assay accuracies and precisions of the
LC-MS/MS were tested as described by Shibata et al. [11].
Cancerous and noncancerous regions in the prostate
Hormone-naïve prostate cancer specimens were obtained
from 10 patients by radical prostatectomy. Each prostate
specimen was cut into two mirror-image 2.5-mm-thick
fragments, each of which was cut into a further 90
sections. All 90 sections were used for the androgen
assays and histopathology diagnosis, to analyze the rela-
tionships between tissue androgen concentrations with
histopathological findings. There was no significant differ-
ence in tissue T or DHT levels between cancerous and
noncancerous sections of individual prostate cancer
sections (mean T levels, p = 0.796; mean DHT levels,
p = 0.912). The tissues used for androgen concentration
measurements in this study were not examined by a
pathologist, because the whole of the samples were used
for androgen measurement. Cancer diagnosis was based
on other, simultaneously-obtained biopsy specimens.
These results indicated that the results of androgen
measurements were unaffected by the use of cancerous
or noncancerous lesions.
Histopathology
All prostate biopsy samples were reviewed by a central
pathologist. Pathological grading was performed according
to the Gleason classification system. Histological diagno-
ses were made by the central pathologist blinded to the
patients’ serum and prostate androgen measurements.
Statistical analysis
We compared tissue and blood androgen levels using
Pearson’s correlation coefficient. If some factors were
found to be correlated with other factors, the correlated
factors were not analyzed simultaneously because of mul-
ticollinearity. We also analyzed the relationships between
T and DHT levels in tissue and blood and prognostic fac-
tors including Gleason score, clinical stage, and % positive
cores by multivariate analyses using a logistic regression
model. All data were analyzed using IBM SPSS ver. 21
software. Each test was two-sided, and p values <0.05 were
considered significant.
Results
Androgen levels in blood and prostate tissue obtained by
needle biopsy
The androgen levels in prostate tissue and peripheral
blood are shown in Table 2. serum T levels were almost
10-fold higher than DHT levels in peripheral blood,
Table 2 Androgen levels in blood and prostate tissue of
patients with prostate cancer (n = 196)
T (blood), pg/mL (median, 95% CI) 3551.0 (3499.8–3902.2)
DHT (blood), pg/mL (median, 95% CI) 330.5 (333.2–382.3)
T (tissue), pg/mg (median, 95% CI) 0.5667 (0.9401–1.3820)
DHT (tissue), pg/mg (median, 95% CI) 7.0625 (8.7513–11.6266)
T: Testosterone; CI: Confidence interval; DHT: Dihydrotestosterone.
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fold higher than tissue T levels. These serum and tissue
androgen levels were similar to those in other reports
concerning prostate cancer patients.
Correlations between T and DHT levels in serum and
prostate tissue are shown in Table 3. There were strong
correlations between T and DHT blood levels (Pearson
correlation coefficient: 0.76996) and we therefore did
not analyze these two factors simultaneously, because of
multicollinearity.
Gleason score
The relationships between Gleason score and androgen
levels and other clinical factors are shown in Table 4.
Logistic regression identified high serum PSA (hazard ra-
tio [HR]: 1.022, p = 0.001), low blood T levels (HR: 0.706,
p = 0.012) and high tissue T levels (HR: 1.388, p = 0.041)
as factors significantly associated with high Gleason score.
Clinical stage
High serum PSA levels (HR: 1.009, p = 0.010) and high
tissue T levels (HR: 1.713, p = 0.002) were significantly
related to advanced clinical stage (Table 4).
% Cancer-positive cores
High serum PSA (HR: 1.017, p = 0.005), low tissue DHT
(HR: 0.878, p = 0.003) and high tissue T levels (HR: 2.432,
p = 0.001) were significantly related to a high % positive
cores (Table 4).
In summary, multivariate analysis demonstrated that
high serum PSA and high tissue T levels were significantly
associated with poor-prognosis factors such as high
Gleason score, advanced clinical stage, and high %
positive cores in men with prostate cancer.Table 3 Correlations between testosterone and
dihydrotestosterone in serum and prostate tissue*
T (blood) T (tissue) DHT (blood) DHT (tissue)
T (blood) 1 0.00901 0.76996 0.08784
T (tissue) 0.00901 1 0.02471 0.25907
DHT (blood) 0.76996 0.02471 1 0.16242
DHT (tissue) 0.08784 0.25907 0.16242 1
*Pearson correlation coefficients.Discussion
The current study demonstrated associations between
high serum PSA and high tissue T levels and poor-
prognosis factors, including high Gleason score, advanced
clinical stage and high % positive cores, in men with pros-
tate cancer. To ensure that histological examination and
androgen measurement were conducted simultaneously,
we measured androgen levels in 90 tissue samples from 10
prostatectomy specimens. Each specimen was cut into
two 2.5-mm-thick mirror-image fragments for androgen
assay and histopathological diagnosis, respectively, allow-
ing direct analysis of the relationship between androgen
levels and histopathological findings. Further, we found
no difference in tissue T levels between cancerous and
noncancerous sections of individual prostate cancer speci-
mens. This indicates that not only prostate cancer cells
themselves but also their surrounding cells might be
responsible for the androgen biosynthesis environment
in prostate cancer tissues. In this study, we measured
androgen levels in single needle prostate cancer biopsies,
but did not confirm if the specimen used for androgen
measurement was cancerous or noncancerous. However,
the above results suggest that the results of the androgen
assay would not be influenced by the presence or absence
of cancerous tissue in the sample.
Several studies of androgen concentrations in prostate
tissues have used bulk tissues such as prostatectomy
specimens, and androgen levels have been measured by
RIA methods [3,4,9,12-14]. However, the present study
demonstrated that: (1) these measurements could be
conducted using the small amounts of tissue obtained by
needle biopsy, rather than excised prostate tissues; and
(2) androgen measurements could be carried out much
more precisely than by RIA, by using LC-MS/MS.
Nishiyama and colleagues used LC-MS/MS and reported
that 47 patients with prostate cancer with Gleason
scores of 7–10 had low DHT levels in the prostate, as
shown by univariate analysis [9]. In the current study,
we found that low tissue DHT levels were associated
with a high % positive cores.
Previous studies of tissue androgen measurements have
had several problems, including small sample sizes,
tissue-handling issues [15], problems with methodological
accuracy and concerns about confounding factors. The
tissue content of DHT decreases rapidly within 2 h at
37°C, and the tissue samples used in the present study
were therefore frozen immediately (at −70°C) until analysis.
To ensure the quality and precision of our measurement
methods, we used prostate tissues spiked with various
amounts of T or DHT to determine the precision of the
LC/MS-MS method, and performed multivariate analysis
after controlling for confounding factors.
Our results confirmed that high T levels in prostate tissue
are related to high Gleason score, advanced clinical stage
Table 4 Correlation between prognostic factors and androgen concentrations in blood and prostate tissue*
Gleason score Clinical stage % positive cores
Parameter ≥8 ≤7 p value HR 95% CI ≥IV ≤III p value HR 95% CI ≥30% <30% p value HR 95% CI
No. of patients 63 130 27 166 50 143
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tissue were also associated with a high % positive cores.
Thomas et al. reported that prostate-tissue expression levels
of 5alpha-reductase type 1 and type 2 were increased in
high-grade, compared with low-grade prostate cancer,
which might explain the relationships between high T and
low DHT prostate tissue levels and poor prognostic factors
[16]. de Winter et al. reported that the intensity of androgen
receptor immunostaining was decreased in more aggressive
tumors [17], suggesting that androgen receptor heterogen-
eity might also offer an explanation of our findings.
Based on our results, we propose that prostate tissue
T level measured by chemical biopsy may be a useful
prognostic factor, in addition to Gleason score, clinical
stage and % positive biopsy cores, for aiding the design of
suitable therapeutic programs for prostate cancer. It is
important that the tissue T level as a prognostic marker
is determined simultaneously with the biopsy, to allow
identification of the individual patient’s prognostic factors
before making decisions about treatment options. More-
over, tissue T could help to subclassify Gleason 7 needle
biopsies into a high-T and normal-T group, to distinguish
between those patients with more aggressive disease and
those with more indolent disease. This would be useful for
selecting suitable patients for active surveillance.
Our results revealed that low serum T was associated
with a Gleason score ≥8. In this regard, Garcia-Cruz et al.
reported that low T was associated with high D’Amico
classification, by multivariate analysis [18]. Hoffman et al.
also reported that low free T indicated an increased risk
of a biopsy Gleason score ≥8 (11% vs 0%, p = 0.025). Our
results are compatible with the hypothesis that low serum
androgen levels may influence poor-prognosis factors in
prostate cancer [19], but no mechanism for this relation-
ship has yet been established.
In our previous study, we first reported that CRPC may
be predicted by prostate tissue T and DHT levels in a single
biopsy specimen, obtained as a chemical biopsy, in patients
undergoing cancer checkups, whether for prostate cancer
or not [11]. Our present finding that high tissue T levels
might be associated with poor prognostic factors may thus
help predict prostate cancer aggressiveness.
The correlation of high tissue T levels with poor prog-
nostic parameters (Gleason score, advanced clinical stage,
high % positive cores) detected in this study suggests that
tissue T may have a prognostic role, though no prognostic
information was available in the current study. Further
studies with larger numbers of patients and longer follow-
up are warranted to confirm the validity of high tissue T
levels as a prognostic marker.
Conclusions
We conclude that high serum PSA levels and high tissue
T levels in men with prostate cancer are significantlyassociated with indicators of poor prognosis, including
advanced clinical stage, high Gleason score and % positive
cores. Tissues T levels determined from biopsy specimens,
in combination with pathological features, may be one
of several useful diagnostic tools for predicting the prog-
nosis and determining a suitable therapeutic program for
patients with prostate cancer.
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